Why is this research being conducted?
This study is being conducted to determine the incremental value of serum and plasma biomarkers in early detection of gestational diabetes in India & to devise a risk-stratification strategy based on biomarker profile for early identification of high-risk pregnancies.
Who is conducting this research?
Principal Investigator
Dr Manju Mamtani, MD
Trustee, Lata Medical Research Foundation, Nagpur, India and General Manager, M&H Research, LLC, San Antonio, TX, USA.
Email: manju.mamtani@utrgv.edu
Co-Principal Investigator
Dr Hemant Kurkarni, MD
Trustee, Lata Medical Research Foundation, Nagpur, India and General Manager, M&H Research, LLC, San Antonio, TX, USA
USA Phone: +1 (210) 602-5537
Email: hemant.kulkarni@utrgv.edu
Co-Investigator
Dr Archana Patel
Lata Medical Research Foundation, Nagpur, India
Co-Investigator
Dr Vaishali Khedikar
Lata Medical Research Foundation, Nagpur, India
Co-Investigator
Dr Seema Parvekar
Medical Superintendent, Daga Memorial Women’s Hospital, Nagpur, India.
We will test the following two hypotheses in the proposed study:
- Early detection of GD before 20 weeks of gestation using combinations of current and novel biomarkers will improve risk-stratification and prediction of pregnancy outcomes.
- The prevalence of GD in urban, central India is comparable to the national average in India.
We propose this study – Markers for Early Risk-stratification of Gestational Diabetes (MERGD) Study – with the following objectives:
PRIMARY OBJECTIVES
- To determine the incremental value of serum and plasma biomarkers in early detection of gestational diabetes in India; and
- To devise a risk-stratification strategy based on biomarker profile for early identification of high-risk pregnancies.
SECONDARY OBJECTIVES
- To estimate the prevalence of gestational diabetes in central India;
- To determine the biomarker-based incremental prediction of maternal and fetal outcomes over and beyond that based on clinical risk factors.
- + MERGD Home
-
Why is this research being conducted?
This study is being conducted to determine the incremental value of serum and plasma biomarkers in early detection of gestational diabetes in India & to devise a risk-stratification strategy based on biomarker profile for early identification of high-risk pregnancies.
- + Team
-
Who is conducting this research?
Principal Investigator
Dr Manju Mamtani, MD
Trustee, Lata Medical Research Foundation, Nagpur, India and General Manager, M&H Research, LLC, San Antonio, TX, USA.
Email: manju.mamtani@utrgv.edu
Co-Principal Investigator
Dr Hemant Kurkarni, MD
Trustee, Lata Medical Research Foundation, Nagpur, India and General Manager, M&H Research, LLC, San Antonio, TX, USA
USA Phone: +1 (210) 602-5537
Email: hemant.kulkarni@utrgv.edu
Co-Investigator
Dr Archana Patel
Lata Medical Research Foundation, Nagpur, India
Co-Investigator
Dr Vaishali Khedikar
Lata Medical Research Foundation, Nagpur, India
Co-Investigator
Dr Seema Parvekar
Medical Superintendent, Daga Memorial Women’s Hospital, Nagpur, India.
- + Hypothesis
-
We will test the following two hypotheses in the proposed study:
- Early detection of GD before 20 weeks of gestation using combinations of current and novel biomarkers will improve risk-stratification and prediction of pregnancy outcomes.
- The prevalence of GD in urban, central India is comparable to the national average in India.
- + Status
-
We propose this study – Markers for Early Risk-stratification of Gestational Diabetes (MERGD) Study – with the following objectives:
PRIMARY OBJECTIVES
- To determine the incremental value of serum and plasma biomarkers in early detection of gestational diabetes in India; and
- To devise a risk-stratification strategy based on biomarker profile for early identification of high-risk pregnancies.
SECONDARY OBJECTIVES
- To estimate the prevalence of gestational diabetes in central India;
- To determine the biomarker-based incremental prediction of maternal and fetal outcomes over and beyond that based on clinical risk factors.
- + Gallery
-